# Zumutor Biologics

Source: https://onco.cc/companies/zumutor-biologics/  
OnCo record `zumutor-biologics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Zumutor Biologics makes an antibody that blocks LLT1, a signal tumours use to switch off natural killer cells, part of the body's first-line immune defence. It is in a first trial in advanced solid tumours, alone and with an existing immunotherapy.

## Summary

Zumutor Biologics Inc. develops antibodies from its INABLR human antibody library platform aimed at natural killer (NK) cell checkpoints. Its timeline says it was founded in Bangalore, India in 2013 and incorporated in the USA in 2015; the home page gives its headquarters as CIC Cambridge, Massachusetts, with an R&D laboratory in Bangalore. Its lead ZM008, an anti-LLT1 antibody, received FDA IND clearance in August 2023 and entered a phase 1 dose-escalation trial (NCT06451497), first as a single agent and then with toripalimab, in advanced solid tumours including non-small cell lung, head and neck, pancreatic and biliary tract cancer; the first patient was dosed in June 2024. The company lists earlier financing from Accel, IDG Ventures, Aarin Capital, KITVEN, Siana Capital and Bharat Innovation Fund, and states it raised a further 7 million US dollars in equity around April 2025. Its first registered cancer trial, NCT06451497, was posted on ClinicalTrials.gov in June 2024.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- HQ: Cambridge, MA
- Type: biotech
- Website: https://zumutor.com/

## Notes

- The company's pages disagree: the home page says 'Formed in 2013' and headquarters in Cambridge, MA, while the About page says 'Founded in 2015' and Woburn, MA. The timeline reconciles these as founding in Bangalore in 2013 and US incorporation in 2015. Read on 29 October 2026.
- Funding amounts are taken from the company's own timeline and are not recorded as funding rows because no dated release for each round was read.
- The pipeline page appears out of date (it still refers to 2021 milestones).

## Sources

- Official website: https://zumutor.com/
- About and timeline: https://zumutor.com/about/
- First patient dosed release, June 2024: https://zumutor.com/wp-content/uploads/2024/06/Zumutor-Announces-First-Patient-Dosed_Final.pdf
- ClinicalTrials.gov: phase 1 trial of ZM008 (NCT06451497): https://clinicaltrials.gov/study/NCT06451497

## Connected records

- cancers: [Biliary tract cancer (all types)](https://onco.cc/cancers/biliary-tract-cancer/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)

---
JSON: https://onco.cc/api/v1/entities/zumutor-biologics.json